Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454828 | 0.88 | HTR2A (0.45) | TDP1ATMALDH1A1MAPTHPGD | |
| SCHEMBL22504535 | 0.82 | DPP8 (0.44) | TDP1ATMALDH1A1MAPTHPGD | |
| SCHEMBL21580364 | 0.81 | ALDH1A1 (0.45) | TDP1ATMALDH1A1MAPTHPGD | |
| SCHEMBL19035167 | 0.81 | ALDH1A1 (0.45) | TDP1ATMALDH1A1MAPTHPGD | |
| SCHEMBL9611933 | 0.78 | ALDH1A1 (0.50) | TDP1ATMALDH1A1MAPTHPGD | |
| SCHEMBL9247606 | 0.78 | ALDH1A1 (0.50) | TDP1ATMALDH1A1MAPTHPGD | |
| SCHEMBL16090421 | 0.78 | ALDH1A1 (0.50) | TDP1ATMALDH1A1MAPTHPGD | |
| SCHEMBL2531926 | 0.78 | HTR2A (0.49) | TDP1ATMALDH1A1MAPTHPGD | |
| SCHEMBL15478418 | 0.74 | HTR2A (0.46) | TDP1ALDH1A1MAPTHPGDHTR2A | |
| SCHEMBL11932224 | 0.73 | HTR2A (0.45) | TDP1ATMALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | TDP1 2209/4885ATM 2071/4885ALDH1A1 1655/4885 |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | MRPL21, MRPL9, NQO2 | TDP1 2209/4885ATM 2071/4885ALDH1A1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.